Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 27, 2014

Filing Date
Filed February 17, 2015
Period End
December 27, 2014
Security
CRL
One revenue dollarkept$0.10
In the record · 2016–202610-K1110-Q338-K118

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 17, 2015. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (CRL) reported fiscal 2014 total revenue of $1.30 billiona (fiscal 2013: $1.17 billion) and operating income of $177.7 million, up from $151.4 million.

Net income attributable to common shareholders was $126.7 millionb, and diluted earnings per share from continuing operations were $2.70, compared with $2.15 in 2013. Revenue growth was led by the Discovery and Safety Assessment (DSA) segment, which rose $105.8 million to $538.2 million, including $71.4 million contributed by the Argenta and BioFocus acquisition. Manufacturing Support grew $30.3 million to $252.1 million, while Research Models and Services (RMS) declined $3.9 million to $507.4 million.

The company completed three acquisitions in 2014: Argenta and BioFocus in April (preliminary purchase price $183.1 millionc net of cash acquired), VivoPath in June, and ChanTest in October ($52.1 million net of cash acquired). Net cash provided by operating activities was $252.1 million, and capital expenditures were $56.9 million. Total debt was $753.8 million at year end, and the company repurchased about 2,093,000 shares for $110.6 million during 2014, leaving $178.5 million remaining under its repurchase authorization.

The company paid no cash dividends and does not intend to pay them in the foreseeable future. The filing also discloses an investigation into inaccurate billing on certain government contracts in the RMS segment, for which the company has reserved approximately $1.5 milliond.

Management reports that the company cannot yet estimate the potential range of loss beyond that reserve. Management also notes that the National Cancer Institute canceled a contract that had been worth $10 to $11 million annually.

Key Highlights

  1. Total revenue rose to $1,297.7 million in 2014 from $1,165.5 million in 2013, an increase of $132.2 million.
  2. Operating income was $177.7 million, up from $151.4 million; diluted EPS from continuing operations was $2.70, versus $2.15 in 2013.
  3. DSA revenue increased $105.8 million to $538.2 million, driven by the Argenta and BioFocus acquisition and higher Safety Assessment revenue.
  4. Net cash provided by operating activities was $252.1 million, versus $209.0 million in 2013; capital expenditures were $56.9 million.
  5. Acquisitions totaled roughly $234.3 million net of cash acquired in 2014, including Argenta/BioFocus, VivoPath and ChanTest.
  6. Total debt was $753.8 million at December 27, 2014, and $178.5 million remained under the stock repurchase authorization.
  7. A government billing investigation resulted in a reserve of approximately $1.5 million, and the company cannot yet estimate losses beyond that amount.

Follow one dollar

Of each $1.00 of revenue in FY2014, Charles River Laboratories International kept $0.10.

  1. Revenue$1.30B100.0%
  2. Cost of revenue−$266.4M20.5%
  3. Gross profit$1.03B79.5%
  4. Operating costs−$853.6M65.8%
  5. Operating income$177.7M13.7%
  6. Interest, other & tax−$51.0M3.9%
  7. Net income$126.7M9.8%
Computed from 10-KFY2014filed February 17, 2015Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2014 revenue went

$1.30B
  • Other operating costs: $584.5M, 45% of revenue
  • SG&A: $269.0M, 21% of revenue
  • Cost of revenue: $266.4M, 21% of revenue
  • Net income: $126.7M, 9.8% of revenue
  • Interest, other & tax: $51.0M, 3.9% of revenue

Kept 9.8% as net incomeNet income $126.7M · 9.8%

Full revenue history →

Financial Statements

FY2014 against FY2013

Line itemFY2014FY2013Change
Revenue$1.30B$1.17B+11.3%
Cost of Revenue$266.42M$272.75M−2.3%
Gross Profit$1.03B$892.78M+15.5%
SG&A Expenses$269.03M$225.69M+19.2%
Operating Income$177.67M$151.40M+17.4%
Interest Expense$11.95M$20.97M−43.0%
Net Income$126.70M$102.83M+23.2%
EPS (Basic)$2.72$2.15+26.5%
EPS (Diluted)$2.66$2.12+25.5%
Shares Outstanding (Basic)46.63M47.74M−2.3%
Shares Outstanding (Diluted)47.56M48.49M−1.9%

Frequently Asked Questions

  1. What drove revenue growth in fiscal 2014?

    Most of the increase came from the Discovery and Safety Assessment segment, which grew $105.8 million, including $71.4 million from the Argenta and BioFocus acquisition. Manufacturing Support also grew $30.3 million, led by the Endotoxin and Microbial Detection business. Research Models and Services declined $3.9 million, mainly in Japan and Europe.

  2. How much debt does the company carry and how is it structured?

    Total debt was $753.8 million at December 27, 2014, up from $663.0 million a year earlier. It consisted of $378.0 million in term loans and $375.5 million drawn on the revolving credit facility under the $970 million credit facility maturing in May 2018. The filing states that a 100-basis-point increase in interest rates would raise annual pre-tax interest expense by approximately $9.3 million.

  3. Does the company pay dividends or repurchase shares?

    The company did not declare or pay cash dividends in the past two years and does not intend to pay them in the foreseeable future. It repurchased approximately 2,093,000 shares for $110.6 million in 2014, and $178.5 million remained on its authorized repurchase program at year end.

  4. What legal or regulatory issues does the filing disclose?

    The company disclosed an investigation, begun in May 2013, into inaccurate billing on certain government contracts in its RMS business, related to work billed but not performed at facilities in Raleigh, North Carolina, and Kingston, New York. It has identified approximately $1.5 million in excess amounts billed since January 1, 2007 and reserved that amount, but cannot estimate the potential range of loss beyond the reserve. The filing also describes a Mauritius arbitration in which the company paid the supplier $1.6 million in September 2014.